
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

March 2023

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

**9th Floor
107 Cheapside
London
EC2V 6DN**

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 15, 2023, OKYO Pharma LTD (the “Company”) issued this 6K announcing that the board of directors of the Company (the “Board” or “Directors”), acting on a recommendation of the Remuneration Committee has awarded the following options (each to acquire one new ordinary share of no par value) (“Options”) to directors and persons discharging managerial responsibility, a copy of which is furnished as Exhibit 99.1

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OKYO Pharma LTD

Date: March 15, 2023

By: /s/ Keeren Shah

Name: Keeren Shah

Title: Chief Financial Officer

3


EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	News Announcement, dated March 15, 2023

4

Exhibit 99.1

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (“UK MAR”).



OKYO Pharma Limited

(“OKYO” or the “Company”)

Grant of options –PDMR dealing

London, March 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today announces that the board of directors of the Company (the “Board” or “Directors”), acting on a recommendation of the Remuneration Committee has awarded the following options (each to acquire one new ordinary share of no par value) (“Options”) to directors and persons discharging managerial responsibility:

Gary S. Jacob	Chief Executive Officer	5,500,000 Options
Keeren Shah	Chief Financial Officer	6,550,000 Options
Dr. Raj Patil	Chief Scientific Officer	15,500,000 Options
Willy Simon	Non-executive director	400,000 Options
John Brancaccio	Non-executive director	1,000,000 Options
Bernard Denoyer	Non-executive director	200,000 Options

The exercise price for all options is £0.025 per share. The options all vest in 4 equal tranches over 4 years, with the first tranche vesting on 14 March 2024, and all options have a life of ten years.

Holders of the Company’s ADS should note that for the purposes of comparison of the quantum of the awards, each ADS held represents 65 ordinary shares.

This information set out below is provided in accordance with Article 19(3) of UK MAR:

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name	PDMRs:	
	Gary S. Jacob	Chief Executive Officer
	Keeren Shah	Chief Financial Officer
	Dr. Raj Patil	Chief Scientific Officer
	Willy Simon	Non-executive director
	John Brancaccio	Non-executive director
	Bernard Denoyer	Non-executive director

2 Reason for the notification

a) Position/status	See 1a) above
b) Initial notification /Amendment	Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	OKYO Pharma Limited
b) LEI	213800VVN5CB56Y15A05

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

- | | | |
|----|---|--|
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of no par value |
| b) | Identification code | ISIN for OKYO Pharma Limited: GG00BD3FV870 |
| c) | Nature of the transaction | Grant of options |
| d) | Price(s) and volume(s) | Price: £0.025 per share |

Volumes:

Gary S. Jacob	5,500,000
Keeren Shah	6,550,000
Dr. Raj Patil	15,500,000
Willy Simon	400,000
John Brancaccio	1,000,000
Bernard Denoyer	200,000

- | | | |
|----|--------------------------|----------------------------|
| e) | Aggregated information | n/a |
| | - Aggregated volume | |
| | - Price | |
| f) | Date of the transaction | 14 March 2023 |
| g) | Place of the transaction | Outside of a trading venue |

For the purposes of UK MAR, the person who arranged the release of this information is Gary S. Jacob, Chief Executive Officer of OKYO.

Enquiries:

OKYO Pharma Limited	Gary S. Jacob, Chief Executive Officer	+44 (0)20 7495 2379
Investor Relations	Paul Spencer	+44 (0)20 7495 2379
Broker	Robert Emmet, Optiva Securities Limited	+44 (0)20 3981 4173

Notes for Editors:

About OKYO

OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 has been shown to produce anti-inflammatory and neuropathic pain-reducing activities in mouse models of DED and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid 'anchor' contained in the drug molecule to enhance the residence time of OK-101 within the ocular environment.

About OKYO

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.

